FDA OKs Genentech’s Tecentriq as Adjuvant Treatment (Correct)

Oct. 15, 2021, 8:35 PM

The U.S. Food and Drug Administration said it approved Genentech’s Tecentriq or atezolizumab, for adjuvant treatment for patients with non-small cell lung cancer, according to the agency’s website.

  • The treatment is for patients who had surgery and platinum-based chemotherapy for adults with Stage II-IIIA non-small cell lung cancer or NSCLC, whose tumors express PD-L1≥1%, as determined by an FDA-approved test, according to a press release from Roche Group, Genentech’s parent company

To view the source of this information click here

(Corrects spelling of company name in first bullet)

To contact the reporter on this story:
Luzi Ann Javier in New ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.